ReleaseWire Connect

Postherpetic Neuralgia - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Postherpetic Neuralgia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Postherpetic Neuralgia prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Postherpetic Neuralgia. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Ultrasonic aspirators have been used in neurosurgery for over 30 years and because of this, it is a relatively mature market with limited growth potential. The majority of the growth in ultrasonic aspirators will occur in their growth in other specialties but growth in the neurological space is fairly stable. In this space the ultrasonic aspirator market has become a replacement business, and technological advances have slowed, therefore unit sales are expected to remain relatively flat over the forecast period. The price for the capital equipment includes the aspirator unit as well as the associated hand pieces, with an average of 1.5 hand pieces per unit. The ASP has come down significantly over the years, with a downward market trend beginning in 2009 due to price pressure but is now relatively stable. Only the capital equipment is included in the market value included in this segment. The capital equipment only accounts for approximately 40% of the total ultrasonic aspirator market value.

Market growth will be propelled by wider acceptance of neuromodulation products, allowing them to be used on a larger proportion of potential patients. In addition, many neuromodulation patients require multiple devices over their lifetimes because the battery life of neuromodulation devices are limited, ranging from three to ten years. Furthermore, the neuromodulation market had a relatively low penetration rate in 2016 and therefore has excellent growth potential. The GES market will be the slowest growing segment in the neuromodulation device market because the procedure has not gained widespread acceptance and the device only has humanitarian device exemption (HDE) status, limiting its usage to 4,000 units per year. The fastest growing segment is projected to be the DBS market. This market will benefit from the expected entry of new competitors into the market, which will lead to increasing ASP and unit sales through the established sales network of St. Jude Medical and potentially Boston Scientific.

Growth in the mid-single digits will be seen in the neurological microscope market over the forecast period. This market includes new expansion business and replacement sales, but does not include refurbished business. Growth will be driven by low growth in both unit sales and ASP. The neurosurgical microscope market is a mature market and the vast majority of units sold are intended to be replacements for existing systems. Though microscopes have a limited lifespan, most of the time they are purchased due to technological advancements before needing to be replaced.

This market encompasses disposable flexible fiberscopes, glass optic endoscopes, reusable flexoscopes, videoscopes, disposable flexible fiberscope adapters and neuroendoscopic hand instruments. This market will continue to increase, driven primarily by growth in procedural volumes for their most common use. Similar trends will be seen in glass optic endoscopes as they have excellent image quality and are preferred for many neurosurgical procedures. ASP in these markets will decrease slightly for competitors to maintain market share.

There will be significant market growth in the mechanical thrombectomy market over the forecast period, driven by growth in unit sales as mechanical thrombectomy is adopted as standard of care for acute ischemic stroke patients. This market includes stent retrievers and suction thrombectomy catheters. The majority of the time a combination of the two categories is used but there a number of factors that can impact treatment decisions, one key factor being physician preference. Studies found new stent retriever devices are superior to first generation aspiration devices but there have been fewer studies comparing the second generation of both categories. Prior to 2012 it was mainly aspiration used and then with the entrance of stent retrievers, they became the primary treatment.

The market value for intrathecal pump will undergo steady growth over the projected period driven by greater patient awareness and technological advancement. Single digit growth in units sold will occur as patient awareness of the benefits of these devices is increasing. There is a high level of patient satisfaction with these devices which leads to high replacement rates and the lower satisfaction rates with neurostimulators drives growth in pumps as well. The market for intrathecal pumps is impacted by trends in the neurostimulation market.

The market for aneurysms clips is projected to experience stable growth after a decade of decline. As endovascular coiling procedures were performed more frequently, the use of aneurysm clips declined. However, the market is now reaching a new saturation point. There are still certain situations where aneurysm clips are preferred and aneurysm clips tend to lead to lower recurrence rates.

The European PIVC market includes three segments: conventional PIVCs, safety PIVCs and midlines. The safety PIVC segment includes three sub-segments: active safety PIVCs, passive safety PIVCs and closed system PIVCs. The midline market comprises three sub-segments: conventional midlines, power-injectable midlines and all-in-one midlines. The PIVC markets in Europe were transformed in 2013 following the implementation of the directive by the Council of the European Union which aims to prevent needlestick injuries to healthcare workers. EU legislation as well as national legislation has put in place significant penalties for facilities that have a high incidence of needlestick injuries. To avoid the legal and health risks hospitals have been transitioning to the use of safety PIVCs. As a result, the conventional PIVC market will continue to decline over the forecast period.

There will be flat growth in the liquid embolics market over the forecast period. The, "A Randomized trial of Unruptured Brain Arteriovenous malformations" (ARUBA) trial compared interventional and conservative treatment of arteriovenous malformations in the brain. Conservative treatment consisted of a regimen of medication while the intervention arm included embolization. The trial was halted in 2013 due to excessive morbidity associated with the interventional arm.